Previous 10 | Next 10 |
home / stock / azncf / azncf news
AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer. The synergies will cover most of the ~$900 million in annual dividend / interest costs with significant growth potential. AstraZeneca is working to position itself...
Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V. Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac....
All four major U.S. equity indexes closed this past week at fresh record highs on signs of progress on stalled stimulus talks and the first regulatory approval of a coronavirus vaccine. Having now rebounded by over 65% from its pandemic lows, the S&P 500 rallied another 1.7% this ...
UK government scoops the US in authorizing the use of the Pfizer/BioNTech vaccine; roll out to commence next week. FDA and EU approval probably not far off. The Pfizer/BioNTech vaccine has first mover advantage. BioNTech stock could experience further gains at least in the short term....
Silverback Therapeutics has filed proposed terms for its $125 million IPO. The firm is advancing programs to treat various highly prevalent forms of cancer. SBTX has produced initially intriguing results but investors will likely need to wait until 2022 to see a meaningful catalys...
Up until recently, dividend stock performance has been a mixed bag with high yielders being notable underachievers. A COVID vaccine-inspired economic recovery in 2021 could put value stocks, dividend payers and cyclicals back into market leadership positions. PEY is well-positione...
Most investors are focused on the bad news affecting REITs. But there has been a lot of very good news lately. We discuss where we find the best opportunities in today's market. For further details see: Very Good News For REITs
Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...
A new week brings updates from both NVAX and MRNA. Detailed numbers from MRNA's COVE study confirm the value of MRNA's vaccine, but is the company's pipeline validated? There may be some delays for NVAX in the US, but how bad is the problem? I see NVAX as a potential long here...
Viraleze antiviral could be effective against SAS-CoV-2 and RSV. Boston Consulting Group is involved in positioning and marketing this preventative/early stage infection product. Viraleze has a fast-track to market in Europe based on antiviral activity, not efficacy of preventing COVI...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...